Alexandre Reuben

This study compares spatial immune architectures in tumor and tumor-adjacent tissues of early-stage NSCLC, finding distinct immune cell densities, spatial patterns, and associations with genomic features and patient outcomes.

The paper identifies TCRs targeting HER2 mutations in NSCLC, showing they recognize mutant epitopes and maintain cytotoxic activity, offering a potential immunotherapy strategy.

This paper introduces TCR-FramePose, a geometric framework for analyzing TCR-pMHC recognition, showing it captures novel structural features beyond conventional descriptors.

The paper develops TimiGP-Response to analyze the tumor immune microenvironment's association with immunotherapy response across multiple cancer types and identifies key immune cell interactions linked to treatment outcomes.

This paper develops pMTnet-omni, an AI system predicting TCR-pMHC binding across species and MHC classes, achieving high accuracy and showing clinical utility in predicting immune-related adverse events.

TimiGP infers functional interactions between immune cells in the tumor microenvironment and identifies their prognostic value using bulk gene expression and survival data.

The paper investigates how anti-cancer immunity evolves from preneoplasia to invasive lung adenocarcinomas, identifying changes in immune response and molecular features that may facilitate immune evasion.

This study examines DNA methylation changes and intra-tumor heterogeneity in lung adenocarcinoma progression, finding increased methylation aberrations and immunosuppression in later-stage lesions.

This study examines genomic and TCR repertoire heterogeneity in SCLC, finding that lower TCR heterogeneity and mutational burden correlate with better survival.